Hepatocytes play a key role in NAFLD progression by synthesizing VEGF-A, which promotes fibrosis and endothelial dysfunction, contributing to disease severity.586 In a murine model of diet-induced NASH, VEGFR2 inhibition reduced steatosis and inflammation, highlighting VEGF signaling as a potential therapeutic target.587 Beyond hepatic angiogenesis, adipose tissue metabolism affects NAFLD development. The gene discussed is VEGFA; the disease is metabolic dysfunction-associated steatohepatitis.